A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension (PAH) has missed its primary endpoint, triggering a 77% crash in the biotech’s share price. The company has paused ...
Missed the trial's primary endpoint: Seralutinib produced a 28.2 m gain in 6MWD versus 13.5 m for placebo (placebo‑adjusted +13.3 m; p=0.032) but failed to meet PROSERA’s pre‑specified two‑sided alpha ...
The General Services Administration has unveiled the first phase of awards under the Alliant 3 governmentwide acquisition contract, a multiple-award vehicle supporting federal IT modernization. The ...
- Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, ...
(MENAFN- EIN Presswire) EINPresswire/ -- As tablets and smartphones show up earlier in childhood, families are rethinking what“good” screen time looks like. Studycat, a company focused on ...
Studycat helps families turn children’s screen time into language learning through play-based apps designed for early learners ages 2–8. Families want screen time that supports development, not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results